What's Happening?
CARsgen Therapeutics presented long-term follow-up results for satricabtagene autoleucel (satri-cel) at the 2026 ASCO Annual Meeting. Satri-cel, an autologous CAR T-cell therapy targeting Claudin18.2, was evaluated as sequential therapy after first-line
treatment in patients with advanced gastric/gastroesophageal junction adenocarcinoma. The study showed a 100% objective response rate among patients with target lesions, with a median progression-free survival of 20.9 months. The therapy demonstrated a manageable safety profile, with no severe cytokine release syndrome or treatment-related deaths reported.
Why It's Important?
The positive long-term results of satri-cel highlight its potential as a promising treatment for advanced gastric cancer, a condition with limited effective therapies. The high response rates and durable survival benefits suggest that satri-cel could significantly improve outcomes for patients with Claudin18.2-positive tumors. This advancement could lead to new treatment protocols and expand the use of CAR T-cell therapies in solid tumors, addressing unmet clinical needs in oncology.
What's Next?
CARsgen plans to expand the application of satri-cel in early-line and perioperative cancer treatments. The company is conducting additional clinical trials to explore its efficacy in other cancer types and treatment settings. Regulatory approvals and successful trial outcomes could lead to broader clinical adoption, potentially establishing satri-cel as a standard treatment for Claudin18.2-positive cancers.
